|
1
|
Gendler SJ, Lancaster CA,
Taylor-Papadimitriou J, et al: Molecular cloning and expression of
human tumor-associated polymorphic epithelial mucin. J Biol Chem.
265:15286–15293. 1990.PubMed/NCBI
|
|
2
|
Gendler S, Taylor-Papadimitriou J, Duhig
T, et al: A highly immunogenic region of a human polymorphic
epithelial mucin expressed by carcinomas is made up of tandem
repeats. J Biol Chem. 263:12820–12823. 1998.
|
|
3
|
Apostolopoulos V, Pietersz GA and McKenzie
IF: MUC1 and breast cancer. Curr Opin Mol Ther. 1:98–103. 1999.
|
|
4
|
Woenckhaus M, Merk J, Stoehr R, et al:
Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small
cell lung cancer. Hum Pathol. 39:126–136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cozzi PJ, Wang J, Delprado W, et al: MUC1,
MUC2, MUC4, MUC5AC and MUC6 expression in the progression of
prostate cancer. Clin Exp Metastasis. 22:565–573. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kigure S: Immunohistochemical study of the
association between the progression of pancreatic ductal lesions
and the expression of MUC1, MUC2, MUC5AC, and E-cadherin. Rinsho
Byori. 54:447–452. 2006.
|
|
7
|
Brossart P, Schneider A, Dill P, Schammann
T, et al: The epithelial tumor antigen MUC1 is expressed in
hematological malignancies and is recognized by MUC1-specific
cytotoxic T-lymphocytes. Cancer Res. 61:6846–6850. 2001.PubMed/NCBI
|
|
8
|
Kawano T, Ito M, Raina D, et al: MUC1
oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic
myelogenous leukemia cells. Cancer Res. 67:11576–11584. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hollingsworth MA and Swanson BJ: Mucins in
cancer: protection and control of the cell surface. Nat Rev Cancer.
4:45–60. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kobayashi M, Iwamatsu A, Shinohara-Kanda
A, et al: Activation of ErbB3-PI3-kinase pathway is correlated with
malignant phenotypes of adenocarcinomas. Oncogene. 22:1294–1301.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pisarev VM, Kinarsky L, Caffrey T, et al:
T cells recognize PD(N/T)R motif common in a variable number of
tandem repeat and degenerate repeat sequences of MUC1. Int
Immunopharmacol. 5:315–330. 2005. View Article : Google Scholar
|
|
12
|
Yang E, Hu XF and Xing PX: Advances of
MUC1 as a target for breast cancer immunotherapy. Histol
Histopathol. 22:905–922. 2007.PubMed/NCBI
|
|
13
|
Tarp MA and Clausen H: Mucin-type
O-glycosylation and its potential use in drug and vaccine
development. Biochim Biophys Acta. 1780:546–563. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mukherjee P, Pathangey LB, Bradley JB, et
al: MUC1-specific immune therapy generates a strong anti-tumor
response in a MUC1-tolerant colon cancer model. Vaccine.
25:1607–1618. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang CK, Sheng CK, Pouniotis D, et al:
Oxidized and reduced mannan mediated MUC1 DNA immunization induce
effective anti-tumor responses. Vaccine. 26:3827–3834. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pejawar-Gaddy S, Rajawat Y, Hilioti Z, et
al: Generation of a tumor vaccine candidate based on conjugation of
a MUC1 peptide to polyionic papillomavirus virus-like particles.
Cancer Immunol Immunother. 59:1685–1696. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deguchi T, Tanemura M, Miyoshi E, et al:
Increased immunogenicity of tumor-associated antigen, mucin 1,
engineered to express alpha-gal epitopes: a novel approach to
immunotherapy in pancreatic cancer. Cancer Res. 70:5259–5269. 2010.
View Article : Google Scholar
|
|
18
|
Choi DH, Woo JK, Choi Y, et al: A novel
chimeric DNA vaccine: Enhancement of preventive and therapeutic
efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock
protein 70 gene. Mol Med Rep. 4:885–890. 2011.PubMed/NCBI
|
|
19
|
Yang H, Cho NH and Seong SY: The
Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces
protective immunity against MUC1-expressing tumours. Clin Exp
Immunol. 158:174–185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sangha R and Butts C: L-BLP25: a peptide
vaccine strategy in non small cell lung cancer. Clin Cancer Res.
13:s4652–s4654. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Apostolopoulos V, Pietersz GA, Tsibanis A,
et al: Pilot phase III immunotherapy study in early-stage breast
cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast
Cancer Res. 8:R272006.
|
|
22
|
Holmberg LA and Sandmaier BM: Vaccination
with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev
Vaccines. 3:655–663. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang Y, Zhang L, Yuan J, et al: Multistep
process through which adenoviral vector vaccine overcomes anergy to
tumor-associated antigens. Blood. 104:2704–2713. 2004. View Article : Google Scholar
|
|
24
|
Boos W and Shuman H: Maltose/maltodextrin
system of Escherichia coli: transport, metabolism, and
regulation. Microbiol Mol Biol Rev. 62:204–229. 1998.PubMed/NCBI
|
|
25
|
Riggs P: Expression and purification of
recombinant proteins by fusion to maltose-binding protein. Mol
Biotechnol. 15:51–63. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kang QZ, Duan GC, Fan QT, et al: Fusion
expression of Helicobacter pylori neutrophil-activating
protein in E. coli. World J Gastroenterol. 11:454–456.
2005.PubMed/NCBI
|
|
27
|
Fernandez S, Palmer DR, Simmons M, et al:
Potential role for Toll-like receptor 4 in mediating Escherichia
coli maltose-binding protein activation of dendritic cells.
Infect Immun. 75:1359–1363. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Q, Ni W, Zhao X, et al: Synergistic
antitumor effects of Escherichia coli maltose binding
protein and Bacillus Calmette-Guerin in a mouse lung carcinoma
model. Immunol Lett. 136:108–113. 2011.
|
|
29
|
Zhao XX, Ma JC, Fang F, et al: Effect of
Escherichia coli maltose-binding protein on mouse Th1 cell
activation. Chin J Immunol. 25:504–507. 2009.
|
|
30
|
Pereira HM, Cleasby A, Pena SSD, et al:
Cloning, expression and preliminary crystallographic studies of the
potential drug target purine nucleoside phosphorylase from
Schistosoma mansoni. Acta Crystallogr D Biol Crystallogr.
59:1096–1099. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vetskova EK, Muhtarova MN, Avramov TI, et
al: Immunomodulatory effects of BCG in patients with recurrent
respiratory papillomatosis. Folia Med (Plovdiv). 55:49–54.
2013.PubMed/NCBI
|
|
32
|
Cautivo KM, Bueno SM, Cortes CM, et al:
Efficient lung recruitment of respiratory syncytial virus-specific
Th1 cells induced by recombinant bacillus Calmette-Guerin promotes
virus clearance and protects from infection. J Immunol.
185:7633–7645. 2010. View Article : Google Scholar
|
|
33
|
Kawai K, Miyazaki J, Joraku A, et al:
Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer:
current understanding and perspectives on engineered BCG vaccine.
Cancer Sci. 104:22–27. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sánchez Olivas MA, Valencia Zavala MP,
Montes Montes J, et al: Immunology and BCG therapeutics. Rev Alerg
Mex. 55:153–163. 2008.(In Spanish).
|
